FINWIRES · TerminalLIVE
FINWIRES

Epiminder Reaches 25 Enrolled Patients in Epilepsy Study

By

Epiminder (ASX:EPI) reached 25 enrolled patients in its DETECT (Diagnosing Epilepsy To EffeCT change) clinical study in the US, according to a Monday filing with the Australian bourse.

The study is evaluating the Minder system, an implantable device for continuous monitoring of brain activity, as a tool to improve clinical decision-making for patients with epilepsy after an inconclusive prolonged electroencephalographic monitoring assessment, the filing said.

The company is progressing toward its next enrolment target of 50 patients, expected in the third quarter of the year, and is on track to meet its stated target of 210 patients by the end of the first half of 2027, per the filing.

What else is happening in Asia?

Asia

Genrix Grants CQ Pharmaceutical Distribution Rights for Myeloma Drug in China, Hong Kong, Macau, Taiwan

Chongqing Genrix Biopharmaceutical (SHA:688443) granted C.Q. Pharmaceutical (SHE:000950) subsidiary Yaoyou Pharmaceutical exclusive development and distribution rights for the GR1803 drug across China and Hong Kong, Macau, and Taiwan.The agreement covers development such as clinical trials, research, and manufacturing, as well as sales, the filing said.The GR1803 velitumimumab drug is indicated for multiple myeloma, a rare form of blood cancer.Yaoyou will pay Genrix up to 600 million yuan in initial payment, listing milestone, and technology transfer milestone payments.Genrix will also be eligible to receive sales royalties of up to a minimum percentage of two digits.

SHA:688443SHE:000950
Asia

Xuan Wu Cloud's CFO Steps Down

Xuan Wu Cloud Technology's (HKG:2392) Chief Financial Officer Ge Ping resigned to devote more time to personal affairs effective May 31, according to a Friday Hong Kong bourse filing.

HKG:2392
Asia

Update: Xi'an Eswin Materials Technology to Invest Up to 40 Million Yuan in Glassmaker's Funding Round

Xi'an Eswin Materials Technology (SHA:688783) will invest up to 40 million yuan in a pre-A+ funding round for Zhuhai Yiyuan Technology, according to a Friday filing with the Shanghai bourse.Zhuhai Yiyuan Technology seeks to raise between 100 million yuan and 200 million yuan in a funding round.The glass manufacturer plans to use the proceeds for capacity expansion, equipment procurement, and technology upgrades.

SHA:688783